Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QT-Cab cabazitaxel QTc study
NL-OMON34078Active, not recruiting
- Sponsor
- Sanofi
- Start
- Oct 2010
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of cabazitaxel in Non-hematologic malignancy, sponsored by Sanofi. Primary endpoint: Change from baseline in QTcF interval. Started Oct 2010; status: active, not recruiting.
02
Drugs
cabazitaxel
03
Conditions
Non-hematologic malignancy
Beyond the preview
Go deeper on NL-OMON34078.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON34078.